Telavancin: a novel lipoglycopeptide antibiotic. - Wikidata - awgldk - TriplyDB

Telavancin: a novel lipoglycopeptide antibiotic.

Telavancin: a novel lipoglycopeptide antibiotic.

http://www.wikidata.org/entity/Q37463589

about

Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study.

P2860

Q24614464-369DD910-ADD3-48CF-B404-DA19014CE722 Q38545589-F906E667-B19D-465A-8589-F50F74CB51F5 Q39520227-B06711F5-1E2B-4B0F-9F82-A21DD96E8BA3

P2860

Telavancin: a novel lipoglycopeptide antibiotic.

http://www.wikidata.org/entity/Q37463589

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Telavancin: a novel lipoglycopeptide antibiotic.

@en

Telavancin: a novel lipoglycopeptide antibiotic.

@nl

type

label

Telavancin: a novel lipoglycopeptide antibiotic.

@en

Telavancin: a novel lipoglycopeptide antibiotic.

@nl

prefLabel

Telavancin: a novel lipoglycopeptide antibiotic.

@en

Telavancin: a novel lipoglycopeptide antibiotic.

@nl

P1433

Q37463589-C1ED8467-16E4-424B-ADDB-FF70E69873BE

P1476

Q37463589-F5CB5C00-CA9A-44AC-90F4-F99058E9EFA3

P2093

Q37463589-586A6095-E09E-4D81-8A3A-747008F8FFCD

Q37463589-895B7E15-6AB3-4FCA-BE2A-708B47D5A456

Q37463589-D3A8283D-F2BA-4888-955F-FB9352E947B8

P2860

Q37463589-0F3798B3-5199-4DF6-AB4E-86C1745EB365

Q37463589-1745686E-B4A9-46EC-B549-10B750DD2BD2

Q37463589-1D25CAE8-3852-4124-AD75-2552E6C36561

Q37463589-2F1B8807-2DE5-49DC-92A2-8BAF14F30F61

Q37463589-36CB4B22-8D98-4004-B31F-372B268EACCA

Q37463589-3B7DA894-F985-4838-B1CD-AA43A0FA3E8D

Q37463589-3D1A6C19-F16A-45AE-9020-6F28ED695905

Q37463589-506EFF8C-8E48-4561-8C48-93474C1F8AB3

Q37463589-63D090FB-9F38-485E-BFF7-877899774B7B

Q37463589-6A0BB147-4B2C-44E7-B161-2CA612D26FF9

P304

Q37463589-5A7E9951-ED50-46D7-ADBE-94DA2072F2A7

P31

Q37463589-AF2F2532-C7D6-466D-8470-D1049BD16AFB

P356

Q37463589-7102C2E9-C799-4C91-AEF1-EBE62A8FA757

P407

Q37463589-179AF93B-242E-4B77-8776-3DB3F49583B5

P433

Q37463589-F20B51BE-BA0B-4A9F-B4E3-689F898DD57E

P478

Q37463589-F3A62050-EF32-42AC-8B95-A19A6A3A7732

P577

Q37463589-8A9032AD-BE25-460D-9DD1-20025D571F49

P698

Q37463589-272646EA-13C3-49B4-ADE5-003E27F2E74B

P356

P1433

Annals of Pharmacotherapy

P1476

Telavancin: a novel lipoglycopeptide antibiotic.

@en

P2093

Donna Sym

http://www.w3.org/2001/XMLSchema#string

Lisa Charneski

http://www.w3.org/2001/XMLSchema#string

Priti N Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

Wound microbiology and associated approaches to wound management

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

Tissue penetration of telavancin after intravenous administration in healthy subjects.

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

P304

928-938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G417

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19401479

http://www.w3.org/2001/XMLSchema#string